Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).

Objective: The REVIDA study aimed to assess the evolution of major depression symptoms in South East Asian (SEA) patients treated with vortioxetine for major depression in real-world clinical practice.

Methods: This non-interventional study was conducted from August 2016 to April 2017. A total of 138 patients (aged 18-65 years) with an active episode of major depression were recruited from Malaysia, Philippines, Singapore and Thailand.

The relationships between clinical characteristics, alcohol and psychotropic exposure, and circadian gene expression in human postmortem samples of affective disorder and control subjects.

Circadian abnormalities may be related to mood disorders. Circadian gene expression was measured in postmortem brain tissue from individuals with affective disorders and controls. Relationships between circadian gene expression, clinical characteristics, and alcohol and psychotropic medication use were noted.

Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders.

Background: Psychiatric disorders and symptoms, ranging from mood dysregulation to delirium, are commonly observed in many neurological disorders. These manifestations complicate the illness and worsen prognosis. Pharmacological treatment options may be limited by the primary neurological illness and side effects.